Why the study?
Is cardiac resynchronization therapy (CRT-P and CRT-D) cost-effective in patients with heart failure and associated conduction disturbances?
Is cardiac resynchronization therapy (CRT-P and CRT-D) cost-effective in patients with heart failure and associated conduction disturbances?
CRT-P and CRT-D appear to be cost-effective treatments for heart failure, generally falling below the $50,000 per QALY threshold, though estimates vary based on modeling assumptions.
Answers are grounded in this paper and cite their sources.
Supports modeling longer horizons for CRT cost-effectiveness; leaves open direct CRT-P versus CRT-D comparisons.
Cardiac resynchronization therapy (CRT) is a treatment of proven efficacy for selected patients with heart failure and associated conduction disturbances. The increasing financial burden that healthcare systems face has increased the interest in cost-effectiveness and cost-utility estimates, focused on devices with defibrillation capabilities (CRT-D), with a high upfront cost, as well as on simpler devices providing only biventricular pacing (CRT-P). Available economic estimates are largely dependent on data source, assumptions, modelling technique, time horizon, and perspective, leading to some variability in cost-effectiveness and cost-utility estimates. As a whole, cost-effectiveness and cost-utility estimates of both CRT-P and CRT-D improve as the time horizon examined is lengthened and appear to be below US$50,000 per quality-adjusted life-year, a threshold value commonly adopted for coverage of healthcare interventions in the USA and quite comparable with similar thresholds used within Europe. Limited data are available on the comparative cost-effectiveness or cost-utility of CRT-P and CRT-D devices. Moreover, more data on the effectiveness and long-term benefits of CRT-D and CRT-P are needed in order to estimate better the value of these treatments in the 'real world, as well as for attempts to improve cost-effectiveness through improved patient selection.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: